Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Some Companies Postpone April Personnel Changes due to Earthquake
April 11, 2011
- Abbott Japan Completes Acquisition of Former Solvay Pharm.
April 11, 2011
- OncoTherapy Starts PII Trial of Angiogenesis Inhibitor
April 11, 2011
- Eisai Licenses Bexarotene to Minophagen
April 11, 2011
- P&G, Teva to Combine Their OTC Businesses
April 11, 2011
- OncoTherapy Begins Recruitment for Cancer Vaccine Trial
April 11, 2011
- Eisai Enters Collaborative R&D Agreement with PRISM BioLab
April 11, 2011
- BI Japan Starts Operations
April 11, 2011
- Collategene Shrinks Ulcers in Buerger's Disease Patients: AnGes MG
April 11, 2011
- Astellas Licenses 3 Compounds to Cardeus
April 11, 2011
- Actos's Use Patent Valid for Combination with α-GIs, SUs, But Not BGs
April 11, 2011
- Mirabegron Improves Key OAB Symptoms in PIII Trial: Astellas
April 11, 2011
- Ono Licenses Cancer Peptide Vaccines from OncoTherapy
April 11, 2011
- Astellas, Pfizer Apply for Additional Indications for Celecox
April 11, 2011
- 5 Remaining Unapproved Drugs/Indications Find Development Sponsors
April 11, 2011
- Wakamoto Aims to Return to Black in FY2011: New President Kamiya
April 11, 2011
- AnGes MG Licenses Transdermal Formulation Technology from MEDRx
April 11, 2011
- Generic Market Share to Reach 6.1% for 2010: Fuji-Keizai
April 11, 2011
- Takeda, DSP Announce Collaboration for Lurasidone in Europe
April 11, 2011
- AXIS Licenses Pilocarpine to Kissei for Development as Fibromyalgia Treatment: SNBL
April 11, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…